Floatz logo

Irinotecan

Bevacizimab

M.D. Anderson Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Bevacizimab cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
M.D. Anderson Cancer Center
Phase 1CC
(+)-VINCRISTINE
M.D. Anderson Cancer Center
Phase 1CC
Calcium folinate pentahydrate
M.D. Anderson Cancer Center
Phase 1CC
Eloxatin
M.D. Anderson Cancer Center
Phase 1CC

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →